Cytori Therapeutics Inc., of San Diego, said it completed a registered direct offering selling shares of its series A 3.6 percent convertible preferred stock for gross proceeds of approximately $13.5 million. The preferred stock is convertible into shares of common stock at the option of the investors at a conversion price of 52 cents each.